Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-11-26 00:00:00 ET · period of report 2024-11-22 · accession 0001714899-24-000234 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-26 | 2024-11-22 | DNLI | Schuth Alexander O. | COFO, Sec | M - OptEx | $0.68 | +20.5K | 198.6K | +12% | +$14.0K |
| D | 2024-11-26 | 2024-11-22 | DNLI | Schuth Alexander O. | COFO, Sec | M - OptEx | $0.00 | -20.5K | 124.6K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-22 | M | A | 20,516 | $0.68 | 198,582 | D | — | — | (F1) Includes 118,810 Unvested RSUs. |
| 2 | Derivative | Stock Option (right to buy) | 2024-11-22 | M | D | 20,516 | $0.00 | 124,562 | D | $0.68 · — to 2025-08-20 | 20,516 Common Stock | (F3) The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. |